Posts

AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi

on

Roche's Tecentriq, Pfizer/Astellas' Padcev and Merck's Keytruda in Bladder Cancer Battle: Recent Updates

on

ImmunityBio Responds to FDA Warning on Anktiva Promotional Claims with New Protocols

on

Padcev-Keytruda Combination Shows Strong Positive Data in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

on

Padcev-Keytruda Combination Succeeds Again in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

on

Tecentriq Demonstrates Survival Benefit in ctDNA-Guided Bladder Cancer Treatment at ESMO 2025

on

J&J's Inlexzo Bladder Cancer Therapy Wins 'Practice-Changing' FDA Approval

on

Phase III Study: Perioperative Padcev & Keytruda Combo Significantly Improves Survival in Bladder Cancer

on

FDA Advisory Committee Narrowly Votes Against UroGen's Bladder Cancer Drug, Calls for Further Studies

on

AstraZeneca opens the door to Imfinzi expansion with trial win in high-risk bladder cancer patients

on

As J&J aims to 'fundamentally change' how bladder cancer type is treated, ImmunityBio plays defense

on

Pfizer's Sasanlimab Shows 32% Reduction in Bladder Cancer Risk But Misses Secondary Endpoints in Phase 3 CREST Trial

on

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

on